[go: up one dir, main page]

MX2018013471A - Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor. - Google Patents

Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor.

Info

Publication number
MX2018013471A
MX2018013471A MX2018013471A MX2018013471A MX2018013471A MX 2018013471 A MX2018013471 A MX 2018013471A MX 2018013471 A MX2018013471 A MX 2018013471A MX 2018013471 A MX2018013471 A MX 2018013471A MX 2018013471 A MX2018013471 A MX 2018013471A
Authority
MX
Mexico
Prior art keywords
pain
new
tetrahydropyrimidodiazepine
dihydropyridodiazepine
subunit
Prior art date
Application number
MX2018013471A
Other languages
English (en)
Other versions
MX383520B (es
Inventor
Almansa Rosales Carmen
Cuevas Cordobés Félix
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of MX2018013471A publication Critical patent/MX2018013471A/es
Publication of MX383520B publication Critical patent/MX383520B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos nuevos de fórmula general (I) que muestran una gran afinidad y actividad respecto a la subunidad a2d de los canales de calcio dependientes de voltaje (VGCC), especialmente la subunidad a2d-1 de los canales de calcio dependientes de voltaje, o una actividad dual respecto a la subunidad a2d de los canales de calcio dependientes de voltaje (VGCC), especialmente la subunidad a2d-1 de los canales de calcio dependientes de voltaje, y el transportador de noradrenalina (NET). La invención también se refiere al proceso para la preparación de dichos compuestos, así como también a las composiciones que los comprenden y su uso como medicamentos.
MX2018013471A 2016-05-06 2017-05-05 Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor MX383520B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382199 2016-05-06
PCT/EP2017/060780 WO2017191304A1 (en) 2016-05-06 2017-05-05 Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions

Publications (2)

Publication Number Publication Date
MX2018013471A true MX2018013471A (es) 2019-06-06
MX383520B MX383520B (es) 2025-03-14

Family

ID=56024209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013471A MX383520B (es) 2016-05-06 2017-05-05 Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor

Country Status (33)

Country Link
US (1) US10590140B2 (es)
EP (1) EP3452475B1 (es)
JP (1) JP6926197B2 (es)
KR (1) KR20190024876A (es)
CN (1) CN109526220B (es)
AR (1) AR108387A1 (es)
AU (1) AU2017260305B2 (es)
BR (1) BR112018072755A2 (es)
CA (1) CA3023379A1 (es)
CO (1) CO2018012002A2 (es)
CY (1) CY1123231T1 (es)
DK (1) DK3452475T3 (es)
ES (1) ES2789676T3 (es)
HR (1) HRP20200668T1 (es)
HU (1) HUE051829T2 (es)
IL (1) IL262825A (es)
LT (1) LT3452475T (es)
ME (1) ME03726B (es)
MX (1) MX383520B (es)
MY (1) MY196791A (es)
PH (1) PH12018502337A1 (es)
PL (1) PL3452475T3 (es)
PT (1) PT3452475T (es)
RS (1) RS60528B1 (es)
RU (1) RU2018141084A (es)
SG (1) SG11201809799WA (es)
SI (1) SI3452475T1 (es)
SM (1) SMT202000365T1 (es)
TN (1) TN2018000372A1 (es)
TW (1) TWI736619B (es)
UA (1) UA123789C2 (es)
WO (1) WO2017191304A1 (es)
ZA (1) ZA201807653B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536941A (ja) * 2017-10-16 2020-12-17 エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. 疼痛及び疼痛に関連する状態を治療するためのプロパンアミン誘導体
MX2020003575A (es) * 2017-10-27 2020-07-22 Esteve Pharmaceuticals Sa Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.
AR113910A1 (es) * 2017-12-04 2020-06-24 Esteve Pharmaceuticals Sa Derivados de o-fenoxi y o-benciloxipropilamino con actividad contra el dolor
WO2019115008A1 (en) * 2017-12-12 2019-06-20 Esteve Pharmaceuticals, S.A. Dialkylaminoarylpiperidinyl-o-phenoxy and o-benzyloxypropylamino derivatives having multimodal activity against pain
WO2019149919A1 (en) * 2018-02-05 2019-08-08 Esteve Pharmaceuticals, S.A. Aminopropoxypiperidinylamido derivatives having multimodal activity against pain
WO2020089263A1 (en) * 2018-10-31 2020-05-07 Esteve Pharmaceuticals, S.A. Optionally nitrogenated isoquinolin-1(2h)-ones and 1h-isochromen- 1-ones for treating pain and pain related conditions
AR116972A1 (es) * 2018-11-02 2021-06-30 Esteve Pharmaceuticals Sa Derivados de alcoxiaminopiridina para tratar dolor y estados relacionados con dolor
US20210395254A1 (en) * 2018-11-02 2021-12-23 Esteve Pharmaceuticals, S.A. New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions
US12384763B2 (en) 2019-02-28 2025-08-12 Osaka University Protein and/or peptide modification molecule

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL362048A1 (en) * 2000-09-27 2004-10-18 Ajinomoto Co, Inc. Benzodiazepine derivative
EP1515709A2 (en) 2002-06-27 2005-03-23 Warner-Lambert Company LLC Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
ES2351367T3 (es) * 2006-02-14 2011-02-03 Vertex Pharmaceuticals Incorporated Dihidrodiazepinas útiles como inhibidores de proteína quinasas.
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)

Also Published As

Publication number Publication date
PH12018502337A1 (en) 2019-07-08
JP6926197B2 (ja) 2021-08-25
BR112018072755A2 (pt) 2019-02-19
PT3452475T (pt) 2020-05-05
MY196791A (en) 2023-05-03
JP2019515039A (ja) 2019-06-06
CN109526220A (zh) 2019-03-26
IL262825A (en) 2018-12-31
SG11201809799WA (en) 2018-12-28
TN2018000372A1 (en) 2020-06-15
KR20190024876A (ko) 2019-03-08
UA123789C2 (uk) 2021-06-02
CN109526220B (zh) 2021-12-21
CA3023379A1 (en) 2017-11-09
EP3452475B1 (en) 2020-02-26
US10590140B2 (en) 2020-03-17
ME03726B (me) 2021-01-20
AU2017260305B2 (en) 2021-04-01
TWI736619B (zh) 2021-08-21
HRP20200668T1 (hr) 2020-10-16
TW201808955A (zh) 2018-03-16
LT3452475T (lt) 2020-05-11
RU2018141084A (ru) 2020-06-08
AR108387A1 (es) 2018-08-15
HUE051829T2 (hu) 2021-03-29
SMT202000365T1 (it) 2020-09-10
RU2018141084A3 (es) 2020-06-11
SI3452475T1 (sl) 2020-07-31
EP3452475A1 (en) 2019-03-13
CY1123231T1 (el) 2021-10-29
ZA201807653B (en) 2019-06-26
AU2017260305A1 (en) 2018-12-13
PL3452475T3 (pl) 2020-08-24
US20190144455A1 (en) 2019-05-16
WO2017191304A1 (en) 2017-11-09
DK3452475T3 (da) 2020-04-27
ES2789676T3 (es) 2020-10-26
RS60528B1 (sr) 2020-08-31
CO2018012002A2 (es) 2019-04-30
MX383520B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
MX2018013471A (es) Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor.
CL2017001017A1 (es) Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018000952A1 (es) Compuestos útiles como inmunomoduladores
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112016023558A2 (pt) compostos úteis como imunomoduladores
BR112019004100A2 (pt) compostos de biarila úteis como imunomoduladores
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
CO2019005059A2 (es) Inhibidores de magl
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CO2019005038A2 (es) Inhibidores de magl
UY36702A (es) Piridinas sustituidas y métodos de uso
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CL2017002957A1 (es) Benzamidas sustituidas y métodos para utilizarlas
MX2021004566A (es) Compuestos terapeuticos.
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
NI202000042A (es) Polimorfos
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2
MX2017016939A (es) Novedosas antagonistas 5-ht2.
CR20180368A (es) Compuestos de dihidroquinolinsulfonamida de alquilo
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2017002405A1 (es) Compuestos bicíclicos fusionados, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades o desordenes relacionados con el fxr.